NEW YORK, NY--(Marketwire - April 17, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the sale of a Blood Volume Analyzer BVA-100® to St. Francis Hospital of Wilmington, Delaware.

As the only full-service hospital in the City of Wilmington, St. Francis is a tremendous resource and provides invaluable services to the Wilmington community. St. Francis Hospital, a member of Catholic Health East under the sponsorship of Hope ministries, has remained committed to providing quality care and has invested in both revenue generating programs and growth initiatives over the past several years. A recently completed multi-year, $17 million capital campaign resulted in a new state-of-the-art Heart Center, an Emergency Department 60% larger than before, renovated facilities, new equipment and enhanced medical programs.

Daxor's Blood Volume Analyzer BVA-100 will be located within St. Francis' Nuclear Medicine Department. The BVA-100 will be utilized to diagnose and treat blood volume abnormalities that often occur in patients with hypertension, heart failure, syncope, anemia, and for pre and post-surgical testing.

The BVA-100 is the only FDA approved diagnostic device of its kind, which can be used by physician offices, diagnostic centers, small to large hospitals and university medical centers to determine a patient's measured and ideal blood volume. By providing the latest technology in blood volume measurement, St. Francis continues its commitment to technological excellence.

Other nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer are The Mayo Clinic, The Cleveland Clinic, and New York University Medical Center. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex™, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Diane Meegan Investor Relations 212-330-8512